Answers are grounded in this paper and cite their sources.
Addition of monoclonal antibodies to metastatic colorectal cancer therapy increases both the survival and treatment costs. This raises the question of economic efficacy of these agents. This review focuses on trials with pharmacoeconomical analysis of chemotherapy and targeted therapy of colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Fedyanin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: